J&K&L HC: Undenied Pleadings are Deemed Admitted by Implication under the CPC || Kerala HC: Transfer Order Pending Disciplinary Proceedings Cannot be Disguised as Punishment || Allahabad HC: GST, Incentives, 0r Festival Advances Cannot be Deducted From Employee’s Retiral Dues || SC: Absconding Accused Cannot Claim Anticipatory Bail Solely Because a Co-Accused Was Acquitted || Supreme Court: District Cricket Bodies Must Adopt Good Governance Voluntarily, Not Follow BCCI Rules || Supreme Court: Post-Award Property Purchasers Cannot Resist Execution of an Arbitral Award || SC: Telecom Spectrum is a Community Resource and its Ownership Cannot be Decided under the IBC || SC: Police Failure to Invoke IPC Provisions Led to Contractor’s Acquittal in Cement Stockpiling Case || SC: Bank’s Internal Classification of Debt as NPA Does Not Determine Limitation under the IBC || Bombay HC: Clarifies Procedure for Executing Foreign Decrees

Merck Sharp & Dohme Corporation & Anr. v. Glenmark Pharmaceuticals Ltd. - (High Court of Delhi) (07 Oct 2015)

Delhi High Court rules in favour of Merck for its diabetes drug

Intellectual Property Rights

The Delhi High Court restrained Glenmark from selling any drug containing Sitagliptin or its derivate. Sitagliptin is the active ingredient used in ‘Januvia’, Merck’s once-daily pill used to lower blood sugar levels in people with Type II diabetes. It had claimed that Glenmark had infringed its patent in the specific chemical. The court dismissed contentions that Glenmark’s product, ‘Zita’, was different from Merck’s product.

Relevant : Read the decision in Merck Sharp & Dohme Corporation v. Glenmark Pharmaceuticals Ltd.

Tags : GLENMARK MERCK PATENT DIABETES

Share :